| Pembrolizumab plus chemotherapy for first-line treatment of metastatic nonsquamous non-small-cell lung cancer: a network meta-analysis AM Frederickson, S Arndorfer, I Zhang, M Lorenzi, R Insinga, ... Immunotherapy 11 (5), 407-428, 2019 | 56 | 2019 |
| Network meta-analysis of food and drug administration-approved treatment options for adults with aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder DM Wingerchuk, I Zhang, A Kielhorn, M Royston, M Levy, K Fujihara, ... Neurology and Therapy 11 (1), 123-135, 2022 | 26 | 2022 |
| Efficacy and safety of treatments for advanced thymic carcinoma after failure of first-line platinum-based chemotherapy: A systematic literature review and meta-analysis A Arunachalam, I Zhang, B Zhao, AM Frederickson, MC Pietanza Lung Cancer 176, 132-139, 2023 | 7 | 2023 |
| Clinical outcomes of chemotherapy-based therapies for previously treated advanced colorectal cancer: a systematic literature review and meta-analysis MM Amonkar, LA Abderhalden, AM Frederickson, A Aksomaityte, ... International Journal of Colorectal Disease 38 (1), 10, 2023 | 2 | 2023 |
| A response to: letter to the editor regarding “Network meta-analysis of Food and Drug Administration-approved treatment options for adults with aquaporin-4 immunoglobulin G … DM Wingerchuk, I Zhang, A Kielhorn, M Royston, M Levy, K Fujihara, ... Neurology and Therapy 11 (3), 1445-1449, 2022 | 2 | 2022 |
| Network Meta-analysis of Ravulizumab and Alternative Interventions for the Treatment of Neuromyelitis Optica Spectrum Disorder SL Clardy, SJ Pittock, O Aktas, J Nakahara, N Isobe, D Centonze, S Fam, ... Neurology and Therapy, 1-15, 2024 | 1 | 2024 |
| Indirect Treatment Comparison of Ravulizumab Versus Approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-Positive (AQP4-IgG+) Neuromyelitis Optica Spectrum … S Clardy, S Pittock, O Aktas, J Nakahara, N Isobe, D Centonze, S Fam, ... Neurology 102 (17_supplement_1), 2511, 2024 | 1 | 2024 |
| Matching-Adjusted Indirect Comparison (MAIC) of Zanubrutinib vs Ibrutinib in Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL) C Thieblemont, K Wang, S Keeping, I Zhang, K Yang, B Tang, ... | 1 | |
| Correction: Network Meta-analysis of Ravulizumab and Alternative Interventions for the Treatment of Neuromyelitis Optica Spectrum Disorder SL Clardy, SJ Pittock, O Aktas, J Nakahara, N Isobe, D Centonze, S Fam, ... Neurology and therapy, 2024 | | 2024 |
| Commentary: Efficacy and safety of the innovative monoclonal antibodies in adults with generalized myasthenia gravis: a Bayesian network analysis I Zhang, JP Jansen, BJ Yungher, A Kielhorn, KS Yee Frontiers in Immunology 15, 1403802, 2024 | | 2024 |
| Matching-Adjusted Indirect Comparison of Brexucabtagene Autoleucel (ZUMA-2) and Pirtobrutinib (BRUIN) in Patients with Relapsed/Refractory Mantle Cell Lymphoma Previously … G Salles, JMH Chen, I Zhang, F Kerbauy, JJ Wu, SW Wade, A Nunes, ... Advances in Therapy 41 (5), 1938-1952, 2024 | | 2024 |
| Matching-Adjusted Indirect Comparison (MAIC) of Brexucabtagene Autoleucel (Brexu-cel) and Pirtobrutinib in Patients with Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL … JMH Chen, I Zhang, JJ Wu, SW Wade, A Nunes, W Peng, JT Snider, ... Blood 142, 5136, 2023 | | 2023 |
| 838P Matching-adjusted indirect comparison (MAIC) of axicabtagene ciloleucel (axi-cel) and epcoritamab (epcor) in relapsed/refractory (R/R) large B cell lymphoma (LBCL) after … OO Oluwole, MD Ray, JM Chen, K Chan, I Zhang, S Keeping, H Smith, ... Annals of Oncology 34, S548, 2023 | | 2023 |
| 839P Matching-adjusted indirect comparison (MAIC) of axicabtagene ciloleucel (axi-cel) and glofitamab (glofit) in relapsed/refractory (R/R) large B cell lymphoma (LBCL) after … FL Locke, JM Chen, K Chan, MD Ray, I Zhang, S Keeping, C Fu, AR Patel, ... Annals of Oncology 34, S549, 2023 | | 2023 |
| P1113: COMPARATIVE EFFICACY OF ZANUBRUTINIB (ZANU) VERSUS RITUXIMAB (RTX) IN RELAPSED MARGINAL ZONE LYMPHOMA (MZL): MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) C Thieblemont, K Wang, S Keeping, I Zhang, K Yang, B Tang, ... HemaSphere 7 (S3), e10013c4, 2023 | | 2023 |
| P1093: MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF ZANUBRUTINIB (ZANU) VERSUS IBRUTINIB (IBRU) IN RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (R/R MZL) C Thieblemont, K Wang, S Keeping, I Zhang, K Yang, B Tang, ... HemaSphere 7 (S3), e8409315, 2023 | | 2023 |
| Matching‐adjusted indirect comparison (MAIC) of zanubrutinib (ZANU) versus ibrutinib (IBRU) in relapsed/refractory marginal zone lymphoma (R/R MZL). C Thieblemont, K Wang, S Keeping, I Zhang, K Yang, B Tang, ... Hematological Oncology 41, 2023 | | 2023 |
| Comparative efficacy of zanubrutinib (ZANU) versus rituximab (RTX) in relapsed marginal zone lymphoma (MZL): Matching-adjusted indirect comparison (MAIC). C Thieblemont, K Wang, S Keeping, I Zhang, K Yang, B Tang, ... Journal of Clinical Oncology 41 (16_suppl), e19526-e19526, 2023 | | 2023 |
| CO110 Systematic Literature Review (SLR) and Meta-Analysis (MA) of Clinical Outcomes for Second-Line and Higher (≥ 2L) Targeted Therapies for Advanced Colorectal Cancer (aCRC) M Amonkar, AM Frederickson, A Aksomaityte, BM Lang, I Zhang, ... Value in Health 25 (12), S39-S40, 2022 | | 2022 |
| Indirect Comparison Analysis of FDA-Approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder (P15-1.007) D Wingerchuk, S Pittock, M Levy, K Fujihara, I Nakashima, F Paul, ... Neurology 98 (18_supplement), 1618, 2022 | | 2022 |
